← Back to Directory

CJC-1295

CJC-1295 with DAC, Modified GRF (1-29) with DAC

Visual ViewRaw DataInteraction Data

Meta Information

ID:cjc-1295
Name:CJC-1295
Schema Version:1.5

Title

CJC-1295

Alternate Names

  • CJC-1295 with DAC
  • Modified GRF (1-29) with DAC

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:
160
High Cost:
320
Cost Type:
monthly
Description:
Sourced from compounding pharmacies or research chemical suppliers.

Summary

CJC-1295 is a long-acting synthetic analogue of Growth Hormone Releasing Hormone (GHRH). It stimulates the pituitary gland to release growth hormone (GH) in a more natural, pulsatile manner, which in turn increases levels of Insulin-like Growth Factor 1 (IGF-1). For healthspan, the goal is to restore youthful GH/IGF-1 levels to support tissue repair, body composition, and sleep quality, though the long-term effects on aging are still debated.

Purpose

A long-acting GHRH analogue to increase endogenous growth hormone.

Card Summary

A long-acting peptide that stimulates natural growth hormone release for tissue repair.

Drug Class

ghrh-analogue

Drugs In Class

Empty Array

Impact

Score:
5.5
Justification:
Effectively raises GH/IGF-1 for body composition, but long-term healthspan impact is unproven.

Evidence

Grade:
B
Score:
5
Justification:
Small human trials exist but lack long-term healthspan or mortality data.

Safety

Score:
7.5
Justification:
Injectable research chemical with unknown long-term risks and potential for serious side effects.

Flags

  • Requires subcutaneous injection and sterile technique.
  • Long-term elevation of IGF-1 is controversially linked to increased cancer risk.
  • Often sourced from unregulated 'research chemical' suppliers, posing quality and purity risks.
  • Should not be used by individuals with active or suspected cancer.
  • Potential side effects include water retention, joint pain, and nerve compression.
  • Interacts with corticosteroids, which can blunt the GH-releasing effect.

Verdict

Potent GH booster with unproven longevity benefits and significant safety concerns.

Created

2026-04-23T23:09:53.421844Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:
subcutaneous_injection
Scope:
  • systemic

Indication

Focus:
healthspan
Description:
CJC-1295 is a long-acting synthetic analogue of Growth Hormone Releasing Hormone (GHRH). It stimulates the pituitary gland to release growth hormone (GH) in a more natural, pulsatile manner, which in ...

Typical Protocol

  • 1000-2000 mcg administered subcutaneously once or twice per week due to its long half-life.